366-367 / 1816
NKI-Curie collaboration at the end of these phase I studies
Differences, similarities
NKI/AVL
Inst Curie
Pat population
Metast breastca, also ER pos
Mets and loc adv breast ca, TN
Dose esc schedule
50, 100, 200, 300
50, 100, 150,200 bid
RT dose
46.69/23 fr, 14.49Gy SIB
50 Gy+/-16 Gy boost sequ
Additional treatment
no surgery
surgery
Translational res
HRD, par assay
HRD, ctDNA, parp1 IHS
Tite CRM
DLT period 12 weeks
DLT period 12 weeks
Late tox
See synopsis
See full protocol
Pat with bolus on skin/WEM
Separate groups in protocol
Not specified